Evidence map›Paper›PMID 37885461›Full record

ArticleTherapeutic advances in medical oncology2023

Intra-individual qualitative and quantitative comparison of [

Géraldine Lens, Niloefar Ahmadi Bidakhvidi, Vincent Vandecaveye, Steven Grauwels, Annouschka Laenen, Wies Deckers, Ronald Peeters, Raphaëla C Dresen, Jeroen Dekervel, Chris Verslype and 7 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Géraldine LensNuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Niloefar Ahmadi BidakhvidiNuclear Medicine, University Hospitals Leuven, Leuven, BelgiumNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Vincent VandecaveyeRadiology, University Hospitals Leuven, Leuven, Belgium.
Steven GrauwelsRadiology, Isala Hospitals, Zwolle, The Netherlands.
Annouschka LaenenInteruniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.
Wies DeckersNuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Ronald PeetersRadiology, University Hospitals Leuven, Leuven, Belgium.
Raphaëla C DresenRadiology, University Hospitals Leuven, Leuven, Belgium.
Jeroen DekervelDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Chris VerslypeDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Kristiaan NackaertsRespiratory Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0003-0754-0002
Paul M ClementGeneral Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
Eric Van CutsemDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Michel KooleNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Karolien GoffinNuclear Medicine, University Hospitals Leuven, Leuven, BelgiumNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Koen Van LaereNuclear Medicine, University Hospitals Leuven, Leuven, BelgiumNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Christophe M DerooseNuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
KU Leuven · BEIsala · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Somatostatin receptor (SSTR) positron emission tomography (PET) is a cornerstone of neuroendocrine tumor (NET) management. Hybrid PET/magnetic resonance imaging (MRI) is now available for NET-imaging, next to PET/computed tomography (CT). Objectives: To determine whether CT or MRI is the best hybrid partner for [ Design: Monocentric, prospective study. Methods: Patients received a same-day [ Results: Twenty-nine patients were included. Primary tumors included 17 gastroenteropancreatic-NETs, 1 colon neuroendocrine carcinoma, 7 lung-NETs and 2 meningiomas. Patient level concordance with PET Conclusions: Compared to SSTR PET/CT, SSTR PET/MRI had a higher patient and organ level concordance for malignant tumoral involvement and number of malignant lesions, with a clear added value in bone and liver specifically.

Indexed as

[68Ga]Ga-DOTATATEKrenning scoreneuroendocrine tumorPET/CTPET/MRISSTR

Identifiers

PMID37885461
PMCPMC10599114
OpenAlexW4387916512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.